37 unchanged sentences
In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control — Integrated Framework (2013) issued by COSO.
−Removed: We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheet and related consolidated statements of operations and comprehensive loss, stockholders’ equity, and cash flows as of and for the year ended December 31, 2020, of the Company and our report dated March 1, 2021, expressed an unqualified opinion on those financial statements.
+Added: We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheet and related consolidated statements of operations and comprehensive loss, stockholders’ equity, and cash flows as of and for the year ended December 31, 2021, of the Company and our report dated February 28, 2022, expressed an unqualified opinion on those financial statements.
Basis for Opinion
15 unchanged sentences
/s/ DELOITTE & TOUCHE LLP
−Removed: San Jose, California
−Removed: March 1, 2021
+Added: San Francisco, California
+Added: February 28, 2022
Other Information
+Added: Disclosure Regarding Foreign Jurisdictions That Prevent Inspections
+Added: Not Applicable.
Certain information required by Part III is omitted from this Annual Report on Form 10-K since we intend to file our definitive proxy statement for our 2022 annual meeting of stockholders (the Definitive Proxy Statement), pursuant to Regulation 14A of the Securities Exchange Act of 1934, as amended, not later than 120 days after December 31, 2021, and certain information to be included in the Definitive Proxy Statement is incorporated herein by reference.
1 unchanged sentence
Information required by this Item is hereby incorporated by reference to our Definitive Proxy Statement.
−Removed: We have adopted a Code of Conduct that applies to our officers, directors and employees which is available on our internet website at www.
−Removed: atarabio.com .
−Removed: The Code of Conduct contains general guidelines for conducting the business of our company consistent with the highest standards of business ethics, and is intended to qualify as a “code of ethics” within the meaning of Section 406 of the Sarbanes-Oxley Act of 2002 and Item 406 of Regulation S-K.
−Removed: In addition, we intend to promptly disclose (1) the nature of any amendment to our Code of Conduct that applies to our principal executive officer, principal financial officer, principal accounting officer or controller or persons performing similar functions and (2) the nature of any waiver, including an implicit waiver, from a provision of our code of ethics that is granted to one of these specified officers, the name of such person who is granted the waiver and the date of the waiver on our website in the future.
Executive Compensation
4 unchanged sentences
Information required by this Item is hereby incorporated by reference to our Definitive Proxy Statement.
−Removed: Principal Accounting Fees and Services
+Added: Principal Accountant Fees and Services
Information required by this Item is hereby incorporated by reference to our Definitive Proxy Statement.
−Removed: Exhibits, Financial Statement Schedules
+Added: Exhibits and Financial Statement Schedules
Financial Statements.
16 unchanged sentences
2014 Employee Stock Purchase Plan
−Removed: Amended and Restated 2018 Inducement Plan
+Added: Second Amended and Restated 2018 Inducement Plan
Form of Restricted Stock Unit Agreement and Restricted Stock Unit Grant Notice under the Inducement Plan
12 unchanged sentences
and Memorial Sloan Kettering Cancer Center, dated as of August 30, 2018
−Removed: Incorporated by Reference
−Removed: Exhibit Description
Amended and Restated Exclusive License Agreement, by and between Atara Biotherapeutics, Inc.
2 unchanged sentences
and the Council of the Queensland Institute of Medical Research, dated September 23, 2016, as amended
+Added: Incorporated by Reference
+Added: Exhibit Description
Second Amended and Restated Research and Development Collaboration Agreement, by and between Atara Biotherapeutics, Inc.
21 unchanged sentences
Commercial Manufacturing Services Agreement, by and between Atara Biotherapeutics, Inc.
−Removed: and Cognate BioServices, Inc., dated December 24, 2019
+Added: and Cognate BioServices, Inc., dated January 1, 2020
+Added: Amendment No.
+Added: 1 to Commercial Manufacturing Services Agreement, between Atara Biotherapeutics, Inc.
+Added: and Cognate BioServices, Inc., dated September 1, 2021
Office Lease, by and between BXP 611 Gateway Center LP and Atara Biotherapeutics, Inc., dated as of December 9, 2015
2 unchanged sentences
dated February 6, 2017
−Removed: Incorporated by Reference
−Removed: Exhibit Description
Research, Development and License Agreement, by and between Atara Biotherapeutics, Inc.
and Bayer AG, dated December 4, 2020
+Added: Lease Agreement between LA Region No.
+Added: 2, LLC and Atara Biotherapeutics, Inc.
+Added: dated March 17, 2021
+Added: First Amended and Restated Exclusive License Agreement by and between Atara Biotherapeutics, Inc.
+Added: and Memorial Sloan Kettering Cancer Center, dated March 22, 2021
+Added: Deed of Amendment Number 1 to Third Amended and Restated License Agreement dated April 21, 2021
+Added: Incorporated by Reference
+Added: Exhibit Description
+Added: Commercialization Agreement by and between Atara Biotherapeutics, Inc.
+Added: and Pierre Fabre Medicament, dated October 2, 2021
+Added: Second Amendment to Lease, by and between Atara Biotherapeutics, Inc.
+Added: and 611 Gateway Center LP, LLC, dated December 9, 2021
+Added: Fourth Amended and Restated Research and Development Collaboration Agreement between Atara Biotherapeutics, Inc.
+Added: and the Counsel of the Queensland Institute of Medical Research, dated December 17, 2021
+Added: Fourth Amended and Restated Exclusive License Agreement between Atara Biotherapeutics, Inc.
+Added: and the Counsel of the Queensland Institute of Medical Research, dated December 17, 2021
+Added: Form of Atara Biotherapeutics, Inc.
+Added: Executive Employment Agreement
List of Subsidiaries
10 unchanged sentences
Inline XBRL Taxonomy Extension Presentation Linkbase Document
−Removed: The cover page from the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, formatted in Inline XBRL
+Added: Cover Page Interactive Data File (embedded within the Inline XBRL document)
Confidential treatment has been granted for a portion of this exhibit.
4 unchanged sentences
Form 10-K Summary
−Removed: Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of South San Francisco, State of California, on the 1 st day of March, 2021.
+Added: Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of South San Francisco, State of California, on the 28 th day of February, 2022.
Atara Biotherapeutics, Inc.
8 unchanged sentences
( principal executive officer )
−Removed: March 1, 2021
+Added: February 28, 2022
/s/ Utpal Koppikar
Utpal Koppikar
−Removed: Chief Financial Officer ( principal financial and accounting officer )
−Removed: March 1, 2021
+Added: Chief Financial Officer
+Added: ( principal financial and accounting officer )
+Added: February 28, 2022
/s/ Ronald Renaud
1 unchanged sentence
Director, Chairman
−Removed: March 1, 2021
−Removed: March 1, 2021
+Added: February 28, 2022
+Added: /s/ Roy Baynes
+Added: Roy Baynes, M.D., Ph.D.
+Added: February 28, 2022
+Added: February 28, 2022
/s/ Matthew K.
−Removed: March 1, 2021
+Added: February 28, 2022
Gallagher, Pharm.D.
−Removed: March 1, 2021
+Added: February 28, 2022
/s/ William K.
−Removed: March 1, 2021
−Removed: /s/ Beth Seidenberg
−Removed: Beth Seidenberg, M.D.
−Removed: March 1, 2021
+Added: February 28, 2022
+Added: /s/ Ameet Mallik
+Added: February 28, 2022
/s/ Maria Grazia Roncarolo
Maria Grazia Roncarolo, M.D.
−Removed: March 1, 2021
−Removed: /s/ Roy Baynes
−Removed: Roy Baynes, M.D., Ph.D.
−Removed: March 1, 2021
+Added: February 28, 2022
+Added: /s/ Beth Seidenberg
+Added: Beth Seidenberg, M.D.
+Added: February 28, 2022
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.